I like this statement.
"We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. "
Fynny how different the fund is described.
In the article:
Armistice Capital is a value-oriented and event-driven fund that was launched in 2012
By our own andre_y_mb • 16 hours ago:
They are an activist hedge fund.
In Antares Pharma Inc (NASDAQ:ATRS), the investor raised its stake to 8.06 million shares from 6.40 million shares held by the fund on June 30. The passive stake is equal to 5.2% of the company’s stock.
Armistice Capital is a value-oriented and event-driven fund that was launched in 2012 by Steven Boyd. During his first year, Mr. Boyd managed to return an impressive 48%. He has gained experience working for a number of investment firms, most recently as an associate at York Capital, as well as previously being a senior research analyst at Senator Investment Group. Mr. Boyd likes to invest money in healthcare and consumer discretionary stocks, and he recently diversified his portfolio to include technology and financial stocks as well.
We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular small-cap stock picks in real time since the end of August 2012. These stocks have returned 118% since then and outperformed the S&P 500 Index by over 60 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.
Maybe you did not understand the question even if it is simple.
What is YOUR estimate of TEVA EPI 2016 sales provided it's AB rated and approved in 2015?
Lets see, at .30 per share it looks to me like you are assuming TEVA to reach a whopping 3% market share of a 1,5Billon market giving ATRS 10% and applying a PE of 10. Not very impressive, Why would Teva persist with a product with such a miserable future?
I would like your unbiased estimate of Teva EPI sales for 2016 provided and AB approval soon.
On top of that you have another 9,055,558 reasons. A lot of them naked..........
But we need the approval.
Hang on andre has said 30 cents since forever...we were once at 5.40 maybe he meant a bump to 5.70?
Because they can...........It might also have something to do with the fact that the injector is made by ATRS and that ATRS will pocket approximately 10% of Tevas EPI sales......What do I know?
For this all to happen TEVA needs to get the thing AB approved.
On August 25 the stock closed at 1.64 so if we close at 1.94 tomorrow.
Well then we'll have to assume that the whole EPIpen thing has been fully baked in to the share price.....
Darn no upsight from here......
I'm sure the FDA will take your view into account when they decide to approve a Teva product or not.
If you cant get the company right you should never count chickens or any kind of feathered animal.
Epi is a TEVA product
I wonder if somehow there was some Deerfield shares that found their way over to Armistice........
Doesn't seem to far fetched....or does it?
Neal thank you for that info.
They must be looking for andre_y_mb's projected 30 cent increase in price on EPI approval and he's predicted 20% market share by 2019.
right now it's up 5cents how on earth do you explain that? The only news we have is your insightful post here.
The question was if copaxone is discounted by 30% why should EPI be discounted by 40%, I don't understand your logic there.
You think they will discount more then I think they will...I have no problem with that.
But why should there be a larger discount on EPI than on Copax(have you got shares in Mylan :o))
"I estimated Epi price around 60% of brand (based on Copaxone generic at 70%)"
Can you explain the logic behind that reasoning Copac 70 so EPI at 60 ????
Thank you for pointing out for the umpteenth time that we did not get to a 1000 scripts last year. That seems to have gotten stuck in your brain. Is it limited storage with low capability to replace and update information that is your problem?
Generic Copaxone is only available to replace the Older version of Tevas product not the new version that requires less frequent injections, that might have something to do with the discount.
Why should Teva leave money on the table with a first generic, I don't think the will give more than 20% max discount.
But that is all i irrelevant until we get approved.